Internal Medicine
EBM Analysis | Does tranexamic acid work for everything? For anything?
29 Jun, 2021 | 09:53h | UTCDoes TXA work for everything? For anything? – First10EM
Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.
28 Jun, 2021 | 10:01h | UTCCommentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND
Commentary on Twitter (thread – click for more)
NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcas
et al. reports BNT162b2 given as a 2nd dose in individuals prime vaccinated with ChAdOx1-S induced a robust immune response, with an acceptable and manageable reactogenicity profile. Read https://t.co/muL0XQxdjG. pic.twitter.com/BxPlXB8EF7— The Lancet (@TheLancet) June 26, 2021
WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads.
28 Jun, 2021 | 09:55h | UTCWHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC
Commentary on Twitter (thread – click for more)
⚠️WEAR MASK EVEN IF VACCINATED—Top @WHO leader urges masks against #DeltaVariant even if 2-dose vaxxed. "Vaccine alone won't stop community transmission. People need to use masks consistently, be in ventilated spaces—even if you're vaccinated" #COVID19🧵https://t.co/qPZTmcy9iW pic.twitter.com/j5V6fbHdoi
— Eric Feigl-Ding (@DrEricDing) June 26, 2021
Delta “Plus”: Scientists say too early to tell risk of Covid-19 variant.
28 Jun, 2021 | 09:53h | UTCDelta plus India: Scientists say too early to tell risk of Covid-19 variant – BBC
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
28 Jun, 2021 | 09:52h | UTCIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Commentary on Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.
28 Jun, 2021 | 09:49h | UTCClinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open
Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay
WHO: Delta variant is ‘most transmissible’ identified so far.
28 Jun, 2021 | 09:58h | UTCWHO: Delta variant is ‘most transmissible’ identified so far – Associated Press
Related: Delta COVID variant fuels global surges, complicates reopenings – CIDRAP AND Delta variant triggers dangerous new phase in the pandemic – Science AND Delta coronavirus variant: scientists brace for impact – Nature AND Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv AND COVID-19: The rise and rise of Delta – Sciblogs AND Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.
28 Jun, 2021 | 09:51h | UTCCo-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America
RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.
28 Jun, 2021 | 09:46h | UTC
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department.
28 Jun, 2021 | 09:43h | UTC
RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.
28 Jun, 2021 | 09:45h | UTCTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)
[Preprint] Long Covid: Third of people infected have long term symptoms.
25 Jun, 2021 | 10:30h | UTCCovid-19: Third of people infected have long term symptoms – The BMJ
Original study (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London
Guideline | Perimenopause and Postmenopause – Diagnosis and Interventions.
28 Jun, 2021 | 09:32h | UTC
AASLD Guideline: Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease.
28 Jun, 2021 | 09:33h | UTC
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
25 Jun, 2021 | 10:37h | UTC
Commentary on Twitter
#COVID19 Associated Pulmonary Aspergillosis
🍄increasing, associated with excess mortality
🍄complex: colonization + tissue/angio-invasion
🍄diagnose? bronchoscopy/BAL
🍄antifungals recommended
🍄consider discontinuating/tapering steroids in no respondershttps://t.co/HhS6wUfibn pic.twitter.com/CJwE3CEXxn— Intensive Care Medicine (@yourICM) June 23, 2021
No evidence yet to suggest Covid vaccine booster is needed, CDC group says.
25 Jun, 2021 | 10:29h | UTCNo evidence yet to suggest Covid vaccine booster is needed, CDC group says – NBC News
Related opinion: 7 Reasons Why We Should Not Need Boosters for COVID-19 – by Monica Ghandi, MD
Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.
25 Jun, 2021 | 10:33h | UTCOriginal Study: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine
Commentary on Twitter
Analysis of a prospectively enrolled cohort of patients with #SARSCoV2 infections reveals a high proportion who experienced #LongCovid symptoms at 6 months, despite being relatively young and having only mild to moderate acute #COVID19 symptoms https://t.co/fuW2QpfJog
— Nature Medicine (@NatureMedicine) June 23, 2021
RCT: Doxycycline for 7 days superior to single-dose azithromycin for the treatment of rectal chlamydia infection.
25 Jun, 2021 | 10:19h | UTCAzithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Doxycycline Superior to Azithromycin for Asymptomatic Rectal Chlamydia in Men – Physician’s Weekly
Commentary on Twitter
Doxycycline is 20% more efficacious than azithromycin for the treatment of rectal chlamydia. Check out the results of our RCT published today in @NEJM.
Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis | NEJM https://t.co/qpjo8VTg8u
— Jane Hocking (@JHocking01) June 23, 2021
Delta COVID variant fuels global surges, complicates reopenings.
25 Jun, 2021 | 10:23h | UTCDelta COVID variant fuels global surges, complicates reopenings – CIDRAP
IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.
25 Jun, 2021 | 10:17h | UTCNews release: IDSA And SHEA Release New Guidelines for Managing Clostridium Difficile Infection – Infectious Diseases Society of America
Commentary on Twitter
🆕🔥🔥🔥Clinical Practice Guideline @IDSAInfo @SHEA_Epi 2021 Focused Update Guidelines on Management of CDI in Adults
Major update💥:for patients with an initial CDI episode, guidelines suggest using fidaxomicin rather than a standard course of vancomycin https://t.co/2iqcoTHqLL pic.twitter.com/2uzZamvkkr— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) June 24, 2021
Perspective | Why are people with obesity more vulnerable to COVID?
25 Jun, 2021 | 10:21h | UTCWhy Are People with Obesity More Vulnerable to COVID? – Scientific American
Evidence-based clinical practice guidelines for management of colorectal polyps.
25 Jun, 2021 | 10:11h | UTC
Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.
24 Jun, 2021 | 10:32h | UTC
Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
24 Jun, 2021 | 10:38h | UTCPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Commentary on Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.
24 Jun, 2021 | 09:52h | UTCRelated: Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose AND Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.